Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Si Ming Li
Institution:
Peking University Cancer Hospital
Observed institution:
Peking University Cancer Hospital
OpenAlex ID:
A5112600679
OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.
2017
·
Chuanliang Cui
, Bin Lian
, et al.
·
Journal of Clinical Oncology
·
10
Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.
2016
·
Jiayi Yu
, Si Ming Li
, et al.
·
Journal of Clinical Oncology
·
8
Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma.
2012
·
Bin Lian
, Li Li Mao
, et al.
·
Journal of Clinical Oncology
·
8
Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.
2017
·
Xue Bai
, Lu Si
, et al.
·
Journal of Clinical Oncology
·
7
A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma.
2017
·
Xinan Sheng
, Xieqiao Yan
, et al.
·
Journal of Clinical Oncology
·
7
A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.
2017
·
Zhihong Chi
, Bixia Tang
, et al.
·
Journal of Clinical Oncology
·
2
A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).
2015
·
Jun Guo
, Xi Nan Sheng
, et al.
·
Journal of Clinical Oncology
·
2
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
2014
·
Si Ming Li
, Yan Kong
, et al.
·
Journal of Clinical Oncology
·
2
A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
2013
·
Lu Si
, Xuan Wang
, et al.
·
Journal of Clinical Oncology
·
2
Mucosal melanoma staging and classification: Firstly established.
2019
·
BIN LIAN
, Chuanliang Cui
, et al.
·
Journal of Clinical Oncology
·
1
Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib.
2015
·
Xi Nan Sheng
, Yan Kong
, et al.
·
Journal of Clinical Oncology
·
1
A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma.
2014
·
Xi Nan Sheng
, Chuan Liang Cui
, et al.
·
Journal of Clinical Oncology
·
1
Association of single nucleotide polymorphisms in AGT, VEGF, and APOE genes with clinical outcome of target therapy in advanced renal cell carcinoma.
2012
·
Li Li Mao
, Lu Si
, et al.
·
Journal of Clinical Oncology
·
1
Primary hypertension to predict progression-free survival of target therapy in patients with metastatic renal cell carcinoma.
2012
·
Zhi Hong Chi
, Li Li Mao
, et al.
·
Journal of Clinical Oncology
·
1
Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors.
2017
·
Bixia Tang
, Zhihong Chi
, et al.
·
Journal of Clinical Oncology
A prospective multicenter phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma (NCT01762150).
2016
·
Xinan Sheng
, Chuanliang Cui
, et al.
·
Journal of Clinical Oncology
A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).
2016
·
Xinan Sheng
, Lu Si
, et al.
·
Journal of Clinical Oncology
The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.
2016
·
Xinan Sheng
, Zhisong He
, et al.
·
Journal of Clinical Oncology
The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma.
2015
·
Bixia Tang
, Zhihong Chi
, et al.
·
Journal of Clinical Oncology
A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma.
2015
·
Xi Nan Sheng
, Lu Si
, et al.
·
Journal of Clinical Oncology
Salvage therapy for metastatic acral or mucosal melanoma: Efficacy and safety analysis of nab-paclitaxel/carboplatin combined with bevacizumab in c-kit/BRAF wild-type pts.
2014
·
Chuan Liang Cui
, Si Ming Li
, et al.
·
Journal of Clinical Oncology
Outcome of isolated limb infusion (ILI) treatment for Chinese acral melanoma patients with/without gene mutations.
2014
·
Zhihong Chi
, Li Li Mao
, et al.
·
Journal of Clinical Oncology
mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.
2012
·
Lu Si
, Xiao wei Xu
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
23
Citation count:
53
H-index:
5
I10-index:
1
Year
Topic
Type